摘要
目的:观察奥美沙坦治疗轻中度原发性高血压的疗效和安全性。方法:121例轻中度原发性高血压病人随机分为奥美沙坦组(n=60)和氯沙坦组(n=61),治疗8 wk,观察2组治疗前后的血压、心率、心电图和血、尿实验室检查的变化。结果:奥美沙坦组与氯沙坦组比较,坐位收缩压和舒张压降低程度都有显著差异,分别为(132±s 14 vs 139±14)mmHg(P＜0．01),(85±9 vs 87±10)mmHg(P＜0．05)。奥美沙坦组降压有效率为85%;每日1次服用奥美沙坦作用可持续24 h,药物降低收缩压和舒张压的谷峰比值均＞50%。2组药物不良反应发生率分别为3%和5%,2组比较无显著差别。结论:奥美沙坦治疗轻、中度原发性高血压病人,能24h平稳降压,谷峰比满意,且耐受性较好。
AIM： To evaluate the efficacy and safety of olmesartan medoxomil in patients with mild to moderate primary hypertension. METHODS： One hundred and twenty-one patients with mild to moderate primary hypertension were randomized into olmesartan group （n = 60） and losartan group （n = 61）. The changes of blood pressure, heart rate, electrocardiogram, blood and urinary laboratory examination were observed before and after the treatment. RESULTS： The systolic blood pressure was （132 ± s 14 vs 139 ± 14） mmHg, and the diastolic blood pressure was （85± 9 vs 87 ± 10） mmHg in olmesartan and losartan group, respectively. There were significant differences of the reduction of systolic and diastolic blood pressure between two groups. The effective rate was 85 % in olmesartan group. A single dose of olmesartan provided 24 hours of antihypertensive effect. The trough to peak ratios of both systolic and diastolic blood pressure were greater than 50 %. Adverse reaction rates observed in two groups were 3 % and 5 %, and there was no significant difference between two groups （P 〉 0.05） . CONCLUSION： Olmesartan is effective and safety in the treatment of mild to moderate hypertension. The effect of olmesartan can maintain for 24 hours and the trough to peak ratios are satisfied. The patients are of better tolerance for olmesartan.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2007年第6期440-442,共3页
Chinese Journal of New Drugs and Clinical Remedies
